A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age

NCT ID: NCT03340064

Last Updated: 2024-07-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-11-30
• Study Completion Date: 2023-07-28

Brief Summary

This is a study to confirm the efficacy of levetiracetam as adjunctive treatment or as monotherapy in pediatric epilepsy subjects aged 1 month to less than 4 years of age with partial seizures.

Detailed Description

The study will consist of 2 periods. The First Period (6 weeks drug treatment) is designed to confirm efficacy of levetiracetam (LEV), and the Second Period is designed to evaluate the long-term efficacy and safety of LEV.

Conditions

Partial Seizures

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Levetiracetam

Subjects aged 1 month to <6 months will be started on levetiracetam (LEV) 14 mg/kg/day at Visit 3. The dose may be increased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months at 2-week intervals to a maximum dose of 42 mg/kg/day. Subjects aged 6 months to <4 years will be started on LEV 20 mg/kg/day at Visit 3. The dose may be increased by LEV 20 mg/kg/day at 2-week intervals to a maximum dose of 60 mg/kg/day.

At Visit 6, subjects may enter the Second Period or enter the Down-Titration Period followed by a Safety Follow-Up Period. Subjects who do not enter the Second Period will be down-titrated. The dose will be decreased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months or by LEV 20 mg/kg/day for subjects aged 6 months to <4 years at 2-week intervals to 0 mg/kg/day.

Group Type: EXPERIMENTAL

Levetiracetam

Intervention Type: DRUG

levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)

Interventions

Levetiracetam

levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)

Intervention Type: DRUG

Other Intervention Names

Keppra; E-Keppra; LEV

Eligibility Criteria

Inclusion Criteria

• Subject must have a diagnosis of epilepsy with partial onset seizures whether or not secondarily generalized
• Male or female from 1 month to <4 years of age. Pre-term infants aged <1 year are to be stratified into an appropriate age category using the best estimate of their corrected gestational age
• For subjects on adjunctive therapy, subject must be on a stable antiepileptic drug (AED) regimen for the Selection and Evaluation Periods of the study. Minor adjustments to the dose of current AEDs are allowed only prior to Visit 1. Monotherapy subjects must not receive AED treatment, receive temporary AED treatment, or switch an AED prior to Visit 1
• Subject weighs >=3.0 kg
• Subject may have Vagal Nerve Stimulation (VNS) which has been implanted for at least 6 months prior to Visit 1; the settings must be stable for at least 2 months prior to Visit 1. Activated VNS must be counted as 1 of the 2 AEDs
• Subject must have experienced at least 2 observable partial seizures, with or without secondary generalization during each 7-day period during the 2 weeks prior to Visit 1. This time period (the 2 weeks prior to Visit 1) will be referred to as the Retrospective Baseline Period. This seizure information (including type, frequency, and date) must have been recorded on a daily record card (DRC) in order to be acceptable
• If epilepsy surgery has been performed prior to study entry, subjects must have a documented failed epilepsy surgery outcome at least 4 weeks prior to Visit 1
• The use of intermittent benzodiazepines, phenobarbitals, and phenytoins is allowed as long as the frequency is not greater than 1 single administration per week for at least 2 weeks prior to Visit 1 and throughout study participation. If benzodiazepines are used more than once a week, they must be considered as 1 of the AEDs

Exclusion Criteria

• Subject has been taking any medication (other than their concomitant AEDs) that influences the central nervous system (CNS) for which they had not been on a stable regimen for at least 1 month prior to Visit 1
• Subject is taking any medication that may interfere with the absorption, distribution, metabolism, or excretion of the concomitant AEDs or levetiracetam (LEV) during the course of the study
• Subject has received any investigational medication or device within 30 days prior to Visit 1
• Subject has taken LEV prior to the study
• Subjects using felbamate who have presented with clinically significant abnormalities and/or hepatic function during felbamate treatment, and subjects who are taking felbamate <1year from the date of Visit 1
• History of status epilepticus requiring hospitalization during the 30 days prior to Visit 1, except for status epilepticus occurring during the first 10 days of life
• Subject has a treatable seizure etiology
• Subject is on a ketogenic diet (concomitantly or within 30 days prior to Visit 1)
• Subject has epilepsy secondary to progressing cerebral diseases
• Subject has a current diagnosis of Rasmussen's syndrome, Landau-Kleffner disease or Lennox-Gastaut syndrome
• Clinically significant deviations from reference range values for renal function or any of the other laboratory parameters required for this study, as determined by the Investigator
• Clinically significant acute or chronic illness (as determined during the physical examination or from other information available to the Investigator)
• Allergy to pyrrolidine derivatives or a history of multiple drug allergies
• Subject is known to have a terminal illness
• Subject has a disorder or condition that may interfere with the absorption, distribution, metabolism, or excretion of medications
• Subject has a history of or presence of pseudoseizures
• Subject has any medical condition that might interfere with the subject's study participation
• Subject has ≥3x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin <35%)

• Minimum Eligible Age: 1 Month
• Maximum Eligible Age: 3 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

UCB Japan Co. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

UCB Cares

Role: STUDY_DIRECTOR

001 844 599 2273

Locations

Ep0100 15

Fukuoka, , Japan

EP0100 3

Hamamatsu, , Japan

EP0100 6

Izumi, , Japan

Ep0100 20

Kobe, , Japan

EP0100 2

Kodaira, , Japan

Ep0100 21

Kofu, , Japan

EP0100 7

Kōshi, , Japan

EP0100 9

Nagakute, , Japan

EP0100 5

Niigata, , Japan

Ep0100 14

Okayama, , Japan

Ep0100 13

Osaka, , Japan

Ep0100 12

Ōbu, , Japan

Ep0100 11

Ōmura, , Japan

Ep0100 18

Saitama, , Japan

EP0100 4

Sapporo, , Japan

Ep0100 10

Sendai, , Japan

Ep0100 19

Sendai, , Japan

Ep0100 16

Shinjuku-ku, , Japan

Ep0100 17

Shinjuku-ku, , Japan

EP0100 1

Shizuoka, , Japan

Ep0100 22

Toyoake, , Japan

Countries

Japan

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

EP0100

Identifier Type: -

Identifier Source: org_study_id